AptaBio Co., Ltd.

DUBLIN--( BUSINESS WIRE )--The "Diabetic Retinopathy - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering. This "Diabetic Retinopathy - Pipeline Insight, 2022" report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Diabetic Retinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Diabetic Retinopathy Understanding Diabetic Retinopathy: Overview Diabetic Retinopathy Emerging Drugs Chapters This segment of the Diabetic Retinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Diabetic Retinopathy Emerging Drugs KSI-301: Kodiak Sciences The Therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with diabetic retinopathy. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in diabetic retinopathy do not meet the promise shown in clinical trials. By extending on mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians. KSI-301 is being developed in Phase III stage of development towards a once every four to six-month treatment regimen - a possible gamechanger that may provide the opportunity for real prevention. Brolucizumab: Novartis Brolucizumab (RTH258) is a humanized single-chain antibody fragment (scFv) and the most clinically advanced, humanized single-chain antibody fragment to reach this stage of development. Single-chain antibody fragments are highly sought after in drug development due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation and drug delivery characteristics. The proprietary innovative structure results in a small molecule (26 kDa) with potent inhibition of, and high affinity to, all VEGF-A isoforms. In preclinical studies, brolucizumab inhibited activation of VEGF receptors through prevention of the ligand-receptor interaction. Increased signaling through the VEGF pathway is associated with pathologic ocular angiogenesis and retinal edema. Inhibition of the VEGF pathway has been shown to inhibit the growth of neovascular lesions, resolve retinal edema and improve vision in patients with chorioretinal vascular diseases. Currently, it is in Phase III stage of development to treat Diabetic Retinopathy. RGX 314: Regenxbio Inc. RGX-314 is being developed as a novel, one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for formation of new leaky blood vessels and retinal fluid accumulation. The company is currently enrolling patients in ALTITUDETM, a Phase II trial for the treatment of diabetic retinopathy using suprachoroidal delivery of RGX-314. Diabetic Retinopathy: Therapeutic Assessment This segment of the report provides insights about the different Diabetic Retinopathy drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Diabetic Retinopathy There are approx. 60+ key companies which are developing the therapies for Diabetic Retinopathy. The companies which have their Diabetic Retinopathy drug candidates in the mid to advanced stage, i.e. Phase III include, Kodiak Sciences Phases The report covers around 60+ products under different phases of clinical development like Late-stage products (Phase III ) Mid-Stage products (Phase II) Early-stage products ( Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates ^- Route of Administration Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Oral Molecule Type Products have been categorized under various Molecule types such as Small molecules Peptide Antibiotics Product Type Drugs have been categorized under various product types like Mono, Combination and Mono/Combination. Diabetic Retinopathy: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Retinopathy therapeutic drugs key players involved in developing key drugs. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Retinopathy drugs. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Retinopathy R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Retinopathy. Diabetic Retinopathy Report Insights Diabetic Retinopathy Pipeline Analysis Therapeutic Assessment Unmet Needs Impact of Drugs Diabetic Retinopathy Report Assessment Pipeline Product Profiles Therapeutic Assessment Pipeline Assessment Inactive drugs assessment Unmet Needs Key Questions Answered Current Treatment Scenario and Emerging Therapies: How many companies are developing Diabetic Retinopathy drugs? How many Diabetic Retinopathy drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Retinopathy? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic Retinopathy therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Diabetic Retinopathy and their status? What are the key designations that have been granted to the emerging drugs? Key Products KSI-301 Brolucizumab Runcaciguat RC 28 E AKB-9778 RG7774 RGX-314 APX3330 ADVM-022 THR-687 OCX 063 BI 764524 MS-553 A selection of companies mentioned in this report includes Ascentage Pharma AptaBio BONAC corporation CCRP Therapeutics Curacle Co Ltd Emerald Bioscience, Inc. EnnovaBio Everglades Biopharma LUYE PHARMA MIRAE CELL BIO Novelty Nobility Inc Noveome Biotherapeutics, Inc. Palatin Technologies Inc PharmAbcine Inc PYC Therapeutics Retinset SL RIBOMIC Shanghai Henlius Biotech OccuRx Kodiak Sciences Novartis Bayer RemeGen Aerpio Therapeutics Hoffman-La-Roche Regenxbio Inc. Ocuphire Pharma, Inc. Adverum Biotechnologies Oxurion MingSight Relin Pharmaceuticals Boehringer Ingelheim NovaGo Therapeutics HanAll Biopharma For more information about this clinical trials report visit https://www.researchandmarkets.com/r/vy3xvo About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

DUBLIN--( BUSINESS WIRE )--The "Diabetic Retinopathy - Pipeline Insight, 2022" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Diabetic Retinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Diabetic Retinopathy Emerging Drugs Chapters This segment of the Diabetic Retinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Diabetic Retinopathy Emerging Drugs KSI-301: Kodiak Sciences The Therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with diabetic retinopathy. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in diabetic retinopathy do not meet the promise shown in clinical trials. By extending on mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians. KSI-301 is being developed in Phase III stage of development towards a once every four to six-month treatment regimen - a possible gamechanger that may provide the opportunity for real prevention. Brolucizumab: Novartis Brolucizumab (RTH258) is a humanized single-chain antibody fragment (scFv) and the most clinically advanced, humanized single-chain antibody fragment to reach this stage of development. Single-chain antibody fragments are highly sought after in drug development due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation and drug delivery characteristics. The proprietary innovative structure results in a small molecule (26 kDa) with potent inhibition of, and high affinity to, all VEGF-A isoforms. In preclinical studies, brolucizumab inhibited activation of VEGF receptors through prevention of the ligand-receptor interaction. Increased signaling through the VEGF pathway is associated with pathologic ocular angiogenesis and retinal edema. Inhibition of the VEGF pathway has been shown to inhibit the growth of neovascular lesions, resolve retinal edema and improve vision in patients with chorioretinal vascular diseases. Currently, it is in Phase III stage of development to treat Diabetic Retinopathy. RGX 314: Regenxbio Inc. RGX-314 is being developed as a novel, one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for formation of new leaky blood vessels and retinal fluid accumulation. The company is currently enrolling patients in ALTITUDETM, a Phase II trial for the treatment of diabetic retinopathy using suprachoroidal delivery of RGX-314. Diabetic Retinopathy: Therapeutic Assessment This segment of the report provides insights about the different Diabetic Retinopathy drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Diabetic Retinopathy There are approx. 60+ key companies which are developing the therapies for Diabetic Retinopathy. The companies which have their Diabetic Retinopathy drug candidates in the mid to advanced stage, i.e. Phase III include, Kodiak Sciences Phases This report covers around 60+ products under different phases of clinical development like Late-stage products (Phase III ) Mid-Stage products (Phase II) Early-stage products ( Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Oral Molecule Type Products have been categorized under various Molecule types such as Small molecules Peptide Antibiotics Product Type Drugs have been categorized under various product types like Mono, Combination and Mono/Combination. Diabetic Retinopathy: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Retinopathy therapeutic drugs key players involved in developing key drugs. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Retinopathy drugs. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Retinopathy R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Retinopathy. Diabetic Retinopathy Report Insights Diabetic Retinopathy Pipeline Analysis Therapeutic Assessment Unmet Needs Impact of Drugs Diabetic Retinopathy Report Assessment Pipeline Product Profiles Therapeutic Assessment Pipeline Assessment Inactive drugs assessment Unmet Needs Key Questions Current Treatment Scenario and Emerging Therapies: How many companies are developing Diabetic Retinopathy drugs? How many Diabetic Retinopathy drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Retinopathy? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic Retinopathy therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Diabetic Retinopathy and their status? What are the key designations that have been granted to the emerging drugs? Key Players Kodiak Sciences Novartis Bayer RemeGen Aerpio Therapeutics Hoffman-La-Roche Regenxbio Inc. Ocuphire Pharma, Inc. Adverum Biotechnologies Oxurion MingSight Relin Pharmaceuticals Boehringer Ingelheim NovaGo Therapeutics HanAll Biopharma Ascentage Pharma AptaBio BONAC corporation CCRP Therapeutics Curacle Co Ltd Emerald Bioscience, Inc. EnnovaBio Everglades Biopharma LUYE PHARMA MIRAE CELL BIO Novelty Nobility Inc Noveome Biotherapeutics, Inc. Palatin Technologies Inc PharmAbcine Inc PYC Therapeutics Retinset SL RIBOMIC Shanghai Henlius Biotech OccuRx Key Products KSI-301 Brolucizumab Runcaciguat RC 28 E AKB-9778 RG7774 RGX-314 APX3330 ADVM-022 THR-687 OCX 063 BI 764524 MS-553 For more information about this report visit https://www.researchandmarkets.com/r/lg24xg

点击上方蓝字 关注CPHI制药在线2020年5月注射剂被正式纳入一致性评价，规定注射剂使用的包装材料和容器的质量和性能不得低于参比制剂，以保证药品质量与参比制剂一致。自此以来，我国注射剂申请通过一致性评价的品种和品规数量快速增加。今年欧盟新版GMP附录推出，对无菌灌装也有了不少新的要求。如何能够既达到国际标准又简化生产过程、提高生产效率是每个药企都在追求的目标。2022年11月18日14:00，阿雷蒙中国医药包装产品线经理卢振举将做客制药在线直播间，为大家讲解欧盟新版GMP附录对轧盖的新要求，以及药品研发全阶段胶塞、西林瓶和设备的适配性等问题。欢迎大家报名一同研讨！讲座安排讲座主题：RayDylyo®：注射剂瓶压盖新标准讲座形式：在线直播讲座时间：2022年11月18日 14:00-15:00讲座大纲欧盟新版GMP附录1有关轧盖的新要求RayDylyo压盖的材质和组成与传统铝塑轧盖相比的优势药品研发全阶段与胶塞、西林瓶以及设备适配性主讲嘉宾卢振举阿雷蒙中国医药包装产品线经理1998年毕业于河北化工学校，后脱产就读于上海大学MBA中心。先后服务于华北制药、苏州胶囊、阿普塔等公司。在原料药、辅料和包装领域拥有20年的市场开发经验。看直播 抽名片夹观看本次直播讲座，还可抽奖赢取阿雷蒙精美商务名片夹一个，快来参与吧！扫码报名直播讲座关于阿雷蒙（ARaymond）阿雷蒙集团(ARaymond Network)拥有157年的历史，是注塑成型、金属加工和装配方面的专家，为汽车、光伏等行业进行紧固解决方案的研发、制造和商业化。    2007年，阿雷蒙医疗（ARaymondlife）开始将这些专业知识应用于医疗行业。    至今，阿雷蒙集团已在全球25个国家建有29间工厂，全球雇员超过7500人。    阿雷蒙医疗，总部位于法国格勒诺布尔，是1968年冬奥会举办地，有“欧洲的硅谷”之称。公司临近全球领先的医药研发和制造基地，包括疫苗、生物医药、动保和诊断试剂等。目前，阿雷蒙医疗的主要产品包括：注射剂瓶和输液瓶用塑料压盖（RayDyLyo®）、压盖适配器（RayDyLyo® VIAL ADAPTER)、无菌植入体包装盒（OR2pack™）等。